Kiniksa Pharmaceuticals International, plc KNSA

KNSA Company Overview

Kiniksa Pharmaceuticals International, plc is a biopharmaceutical company focused on the development and commercialization of therapies for autoimmune and inflammatory diseases. The company operates within the biopharmaceuticals and specialty therapeutics industries, with an emphasis on rare and underserved inflammatory conditions. Its primary revenue driver is Arcalyst® (rilonacept), an interleukin‑1 (IL‑1) inhibitor approved for the treatment of recurrent pericarditis and reduction of risk of recurrence, which represents the company’s core commercial product.

Founded in 2015, Kiniksa was established to identify, acquire, and develop late-stage clinical assets rather than pursuing early-stage discovery. The company evolved through strategic licensing and acquisition of clinical-stage programs, most notably acquiring global development and commercialization rights to rilonacept from Regeneron Pharmaceuticals, Inc. This asset-centric model differentiates Kiniksa from traditional discovery-focused biotech companies and allows it to concentrate resources on targeted indications with defined regulatory and commercial pathways.